The fundamental links between climate change and marine plastic pollution

Plastic pollution and climate change have commonly been treated as two separate issues and sometimes are even seen as competing. Here we present an alternative view that these two issues are fundamentally linked. Primarily, we explore how plastic contributes to greenhouse gas (GHG) emissions from the beginning to the end of its life cycle. Secondly, we show that more extreme weather and floods associated with climate change, will exacerbate the spread of plastic in the natural environment. Finally, both issues occur throughout the marine environment, and we show that ecosystems and species can be particularly vulnerable to both, such as coral reefs that face disease spread through plastic pollution and climate-driven increased global bleaching events. A Web of Science search showed climate change and plastic pollution studies in the ocean are often siloed, with only 0.4% of the articles examining both stressors simultaneously. We also identified a lack of regional and industry-specific life cycle analysis data for comparisons in relative GHG contributions by materials and products. Overall, we suggest that rather than debate over the relative importance of climate change or marine plastic pollution, a more productive course would be to determine the linking factors between the two and identify solutions to combat both crises

Pyrethroid resistance and its inheritance in a field population of Hippodamia convergens (Guérin-Méneville) (Coleoptera: Coccinellidae)

Citation: Rodrigues, A. R. S., Ruberson, J. R., Torres, J. B., Siqueira, H. A. A., & Scott, J. G. (2013). Pyrethroid resistance and its inheritance in a field population of Hippodamia convergens (Guérin-Méneville) (Coleoptera: Coccinellidae). Retrieved from http://krex.ksu.eduThe convergent lady beetle (CLB), Hippodamia convergens (Guérin-Méneville), a species widely distributed and used in biological control, has exhibited high survival under field and laboratory conditions when treated with field rates of the pyrethroid λ-cyhalothrin, a highly unusual phenomenon for a natural enemy. This work investigated and characterized the phenomenon of pyrethroid resistance in a population of this species collected in Georgia, USA. The mechanism and level of resistance were evaluated by treating parental populations with λ-cyhalothrin ± piperonyl butoxide (PBO). The inheritance bioassay utilized parental crosses and backcrosses between parental populations to obtain testable progenies. Adult beetles from populations and progenies were topically treated with different doses of λ-cyhalothrin (technical grade) to calculate knockdown (KD) and lethal (LD) doses, and to investigate the dominance based on a single dose and whether resistance is autosomal and monogenic (null hypothesis). Genetic variation in the parental populations was examined by applying a discriminating dose for resistant individuals (0.5 g/L). The data indicate that resistance is due to at least two factors: knockdown resistance and enzymatic detoxification of the insecticide. The knockdown effect is recessive and linked to the X-chromosome. Variability in proportions of individuals within families dying following knockdown indicated genetic variation in the resistant population. Further studies should be done to investigate the role of sex linked inheritance of resistance in the species and interactions of the various mechanisms involved in resistance

A longitudinal resource for population neuroscience of school-age children and adolescents in China

During the past decade, cognitive neuroscience has been calling for population diversity to address the challenge of validity and generalizability, ushering in a new era of population neuroscience. The developing Chinese Color Nest Project (devCCNP, 2013-2022), the first ten-year stage of the lifespan CCNP (2013-2032), is a two-stages project focusing on brain-mind development. The project aims to create and share a large-scale, longitudinal and multimodal dataset of typically developing children and adolescents (ages 6.0-17.9 at enrolment) in the Chinese population. The devCCNP houses not only phenotypes measured by demographic, biophysical, psychological and behavioural, cognitive, affective, and ocular-tracking assessments but also neurotypes measured with magnetic resonance imaging (MRI) of brain morphometry, resting-state function, naturalistic viewing function and diffusion structure. This Data Descriptor introduces the first data release of devCCNP including a total of 864 visits from 479 participants. Herein, we provided details of the experimental design, sampling strategies, and technical validation of the devCCNP resource. We demonstrate and discuss the potential of a multicohort longitudinal design to depict normative brain growth curves from the perspective of developmental population neuroscience. The devCCNP resource is shared as part of the "Chinese Data-sharing Warehouse for In-vivo Imaging Brain" in the Chinese Color Nest Project (CCNP) - Lifespan Brain-Mind Development Data Community (https://ccnp.scidb.cn) at the Science Data Bank

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo